157 related articles for article (PubMed ID: 38696902)
1. Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives.
Jiménez-Labaig P; Rullan A; Braña I; Hernando-Calvo A; Moreno V; Doger B; Bitar G; Ap Dafydd D; Melcher A; Harrington KJ
Cancer Treat Rev; 2024 Jun; 127():102746. PubMed ID: 38696902
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
[TBL] [Abstract][Full Text] [Related]
3. The molecular characteristics of recurrent/metastatic HPV-positive head and neck squamous cell carcinoma: A systematic review of the literature.
Flach S; Maniam P; Hey SY; Manickavasagam J
Clin Otolaryngol; 2024 Jul; 49(4):384-403. PubMed ID: 38658385
[TBL] [Abstract][Full Text] [Related]
4. The role of intratumoral therapy with cisplatin/epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck.
Wenig BL; Werner JA; Castro DJ; Sridhar KS; Garewal HS; Kehrl W; Pluzanska A; Arndt O; Costantino PD; Mills GM; Dunphy FR; Orenberg EK; Leavitt RD
Arch Otolaryngol Head Neck Surg; 2002 Aug; 128(8):880-5. PubMed ID: 12162764
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study.
Papa S; Adami A; Metoudi M; Beatson R; George MS; Achkova D; Williams E; Arif S; Reid F; Elstad M; Beckley-Hoelscher N; Douri A; Delord M; Lyne M; Shivapatham D; Fisher C; Hope A; Gooljar S; Mitra A; Gomm L; Morton C; Henley-Smith R; Thavaraj S; Santambrogio A; Andoniadou C; Allen S; Gibson V; Cook GJR; Parente-Pereira AC; Davies DM; Farzaneh F; Schurich A; Guerrero-Urbano T; Jeannon JP; Spicer J; Maher J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37321663
[TBL] [Abstract][Full Text] [Related]
6. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
7. International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancers.
Liem X; de Baère T; Vivar OI; Seiwert TY; Shen C; Pápai Z; Moreno V; Takácsi-Nagy Z; Helfferich F; Thariat J; Gooi Z; Yom SS; Bossi P; Ferris RL; Hackman TG; Le Tourneau C; Rodriguez J; Hoffmann C
Head Neck; 2024 Jun; 46(6):1253-1262. PubMed ID: 38600434
[TBL] [Abstract][Full Text] [Related]
8. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in head and neck squamous cell carcinoma: An updated review.
Parmar K; Mohamed A; Vaish E; Thawani R; Cetnar J; Thein KZ
Cancer Treat Res Commun; 2022; 33():100649. PubMed ID: 36279709
[TBL] [Abstract][Full Text] [Related]
12. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
13. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy--phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol.
Wollenberg B; Kastenbauer ; Mundl H; Schaumberg J; Mayer A; Andratschke M; Lang S; Pauli C; Zeidler R; Ihrler S; Löhrs ; Naujoks K; Rollston R
Hum Gene Ther; 1999 Jan; 10(1):141-7. PubMed ID: 10022539
[TBL] [Abstract][Full Text] [Related]
15. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.
Tian Y; Lin J; Tian Y; Zhang G; Zeng X; Zheng R; Zhang W; Yuan Y
Int J Cancer; 2018 Jun; 142(11):2198-2206. PubMed ID: 29143328
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.
Teknos TN; Grecula J; Agrawal A; Old MO; Ozer E; Carrau R; Kang S; Rocco J; Blakaj D; Diavolitsis V; Kumar B; Kumar P; Pan Q; Palettas M; Wei L; Baiocchi R; Savvides P
Invest New Drugs; 2019 Aug; 37(4):702-710. PubMed ID: 30569244
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of Immunotherapies in Head and Neck Cancers Using Biomaterial-Based Treatment Strategies.
Sunga GM; Hartgerink J; Sikora AG; Young S
Tissue Eng Part C Methods; 2023 Jun; 29(6):257-275. PubMed ID: 37183412
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy of head and neck cancer : Highlights of the ASCO and ESMO annual meetings 2021].
Theodoraki MN; Laban S; Hoffmann TK
HNO; 2022 Apr; 70(4):271-277. PubMed ID: 35037989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
